ICU Medical (ICUI) Expected to Announce Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is projected to release its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of $1.68 per share and revenue of $541.2040 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

ICU Medical Stock Performance

Shares of ICUI opened at $147.73 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. The stock has a 50-day moving average of $148.91 and a two-hundred day moving average of $134.92. The stock has a market cap of $3.65 billion, a P/E ratio of -476.53 and a beta of 0.79. ICU Medical has a one year low of $107.00 and a one year high of $165.17.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Millennium Management LLC lifted its position in shares of ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares in the last quarter. UBS Group AG lifted its holdings in ICU Medical by 239.8% during the third quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after purchasing an additional 272,782 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of ICU Medical by 34.0% in the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock valued at $96,393,000 after purchasing an additional 203,746 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of ICU Medical by 16.9% during the third quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier’s stock worth $104,718,000 after purchasing an additional 126,072 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of ICU Medical by 75.6% during the 3rd quarter. Wellington Management Group LLP now owns 237,789 shares of the medical instruments supplier’s stock worth $28,525,000 after purchasing an additional 102,356 shares during the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ICUI. Wall Street Zen lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Piper Sandler boosted their target price on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, KeyCorp increased their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $175.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.